| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-132 |
Sentence |
denotes |
Association of endothelia nitric oxide synthase gene rs1799983 polymorphism with susceptibility to prostate cancer: a meta-analysis. |
| T1 |
0-132 |
Sentence |
denotes |
Association of endothelia nitric oxide synthase gene rs1799983 polymorphism with susceptibility to prostate cancer: a meta-analysis. |
| TextSentencer_T2 |
133-312 |
Sentence |
denotes |
Genetic polymorphism of endothelial nitric oxide synthase (NOS3) rs1799983 (Glu298Asp) has been implicated to alter the risk of prostate cancer, but the results are controversial. |
| T2 |
133-312 |
Sentence |
denotes |
Genetic polymorphism of endothelial nitric oxide synthase (NOS3) rs1799983 (Glu298Asp) has been implicated to alter the risk of prostate cancer, but the results are controversial. |
| TextSentencer_T3 |
313-441 |
Sentence |
denotes |
Two investigators independently searched the PubMed, Cochrane Library, and Embase electronic databases up to September 30, 2013. |
| T3 |
313-441 |
Sentence |
denotes |
Two investigators independently searched the PubMed, Cochrane Library, and Embase electronic databases up to September 30, 2013. |
| TextSentencer_T4 |
442-564 |
Sentence |
denotes |
Summary odds ratios (OR) and 95 % confidence interval (CI) for rs1799983 polymorphism and prostate cancer were calculated. |
| T4 |
442-564 |
Sentence |
denotes |
Summary odds ratios (OR) and 95 % confidence interval (CI) for rs1799983 polymorphism and prostate cancer were calculated. |
| TextSentencer_T5 |
565-668 |
Sentence |
denotes |
Statistical analysis was performed with the software program Review Manage, version 5.0 and Stata 11.0. |
| T5 |
565-668 |
Sentence |
denotes |
Statistical analysis was performed with the software program Review Manage, version 5.0 and Stata 11.0. |
| TextSentencer_T6 |
669-761 |
Sentence |
denotes |
A total of 7 independent studies, including 1,792 cases and 2,411 controls, were identified. |
| T6 |
669-761 |
Sentence |
denotes |
A total of 7 independent studies, including 1,792 cases and 2,411 controls, were identified. |
| TextSentencer_T7 |
762-984 |
Sentence |
denotes |
Our analysis suggested that rs1799983 was associated with prostate cancer risk in overall population under dominant model (OR = 1.15, 95%CI = 1.01-1.30, P = 0.03) and allelic model (OR = 1.11, 95%CI = 1.00-1.22, P = 0.04). |
| T7 |
762-984 |
Sentence |
denotes |
Our analysis suggested that rs1799983 was associated with prostate cancer risk in overall population under dominant model (OR = 1.15, 95%CI = 1.01-1.30, P = 0.03) and allelic model (OR = 1.11, 95%CI = 1.00-1.22, P = 0.04). |
| TextSentencer_T8 |
985-1140 |
Sentence |
denotes |
In the subgroup analysis, we detected no association between rs1799983 polymorphism and prostate risk in Caucasian population under all the genetic models. |
| T8 |
985-1140 |
Sentence |
denotes |
In the subgroup analysis, we detected no association between rs1799983 polymorphism and prostate risk in Caucasian population under all the genetic models. |
| TextSentencer_T9 |
1141-1294 |
Sentence |
denotes |
This meta-analysis showed the evidence that NOS3 rs1799983 polymorphism was associated with a risk of prostate cancer development in overall populations. |
| T9 |
1141-1294 |
Sentence |
denotes |
This meta-analysis showed the evidence that NOS3 rs1799983 polymorphism was associated with a risk of prostate cancer development in overall populations. |
